Abstract
α-Mannosidosis, OMIM #248500, is an autosomal recessive lysosomal storage disease caused by acidic α-mannosidase deficiency. Treatment options include bone marrow transplantation (BMT) and, possibly in the future, enzyme replacement therapy. Brain magnetic resonance spectroscopy (MRS) enables non-invasive monitoring of cerebral treatment effect. Accumulated cerebral mannose-containing oligosaccharides were demonstrated by MRS in a patient who at age 2 years and 11 months received a BMT from a haploidentical non-carrier sibling. The cerebral mannose-containing oligosaccharides had disappeared as early as 9½ months after BMT. MRS furthermore demonstrated the persistent treatment effect at regular intervals up to 5½ years after BMT. MRS is a non-invasive tool that can demonstrate the effect of BMT treatment. Likewise, MRS may be used to demonstrate the cerebral effect of other potential treatments such as enzyme replacement therapy.
Electronic supplementary material: The online version of this chapter (doi:10.1007/8904_2013_221) contains supplementary material, which is available to authorized users.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abraham D, Daniel P, Dell A et al (1986) Structural analysis of the major urinary oligosaccharides in feline alpha-mannosidosis. Biochem J 233(3):899–904
Ara JR, Mayayo E, Marzo ME et al (1999) Neurological impairment in alpha-mannosidosis: a longitudinal clinical and MRI study of a brother and sister. Childs Nerv Syst 15(8):369–371
Avenarius DF, Svendsen JS, Malm D (2011) Proton nuclear magnetic resonance spectroscopic detection of oligomannosidic n glycans in alpha-mannosidosis: a method of monitoring treatment. J Inherit Metab Dis 34(5):1023–1027
Blanz J, Stroobants S, Lüllmann-Rauch R et al (2008) Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Hum Mol Genet 17:3437–3445
Chester MA, Lundblad A, Öckerman PA et al (1982) Mannosidosis. In: Durand P, O'Brian J (eds) Genetic errors of glycoprotein metabolism. Edi-Ermes, Milan, Italy, pp 89–120
Crawley AC, King B, Berg T et al (2006) Enzyme replacement therapy in alpha-mannosidosis guinea-pigs. Mol Genet Metab 89(1–2):48–57
Dietemann JL, Filippi de la Palavesa MM, Tranchant C et al (1990) MR findings in mannosidosis. Neuroradiology 32(6):485–487
Elberling TV, Danielsen ER, Rasmussen AK et al (2003) Reduced myo-inositol and total choline measured with cerebral MRS in acute thyrotoxic Graves’ disease. Neurology 60(1):142–145
Gutschalk A, Harting I, Cantz M et al (2004) Adult alpha-mannosidosis: clinical progression in the absence of demyelination. Neurology 63:1744–1746
Hård K, Mekking A, Kamerling JP et al (1991) Different oligosaccharides accumulate in the brain and urine of a cat with alpha-mannosidosis: structure determination of five brain-derived and seventeen urinary oligosaccharides. Glycoconj J 8(1):17–28
Magnitsky S, Vite CH, Delikatny EJ et al (2010) Magnetic resonance spectroscopy of the occipital cortex and the cerebellar vermis distinguishes individual cats affected with alpha-mannosidosis from normal cats. NMR Biomed 23(1):74–79
Malm D, Nilssen Ø (2008) Alpha-mannosidosis. Orphanet J Rare Dis 3:21
Niemann S, Beck M, Seidel G et al (1996) Neurology of adult alpha-mannosidosis. J Neurol Neurosurg Psychiatry 61(1):116–117
Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30(6):672–679
Roces DP, Lüllmann-Rauch R, Peng J et al (2004) Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study. Hum Mol Genet 13(18):1979–1988
Strecker G, Fournet B, Bouquelet S et al (1976) Chemistry of urinary mannosides excreted in mannosidosis 58(5):579–586
Takahashi Y, Sukegawa K, Aoki M et al (2001) Evaluation of accumulated mucopolysaccharides in the brain of patients with mucopolysaccharidoses by 1H-magnetic resonance spectroscopy before and after bone marrow transplantation. Pediatr Res 49(3):349–355
Van Halbeek H, Dorland L, Veldink GA et al (1980) A 500 MHz 1H NMR study of urinary oligosaccharides from patients with mannosidosis. FEBS Lett 121(1):71–77
Vite CH, Magnitsky S, Aleman D et al (2008) Apparent diffusion coefficient reveals gray and white matter disease, and T2 mapping detects white matter disease in the brain in feline alpha-mannosidosis. AJNR Am J Neuroradiol 29(2):308–313
Vite CH, McGowan JC, Braund KG et al (2001) Histopathology, electrodiagnostic testing, and magnetic resonance imaging show significant peripheral and central nervous system myelin abnormalities in the cat model of alpha-mannosidosis. J Neuropathol Exp Neurol 60(8):817–828
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Frits Wijburg, MD, PhD Competing interests: None declared
Rights and permissions
Copyright information
© 2013 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Danielsen, E.R., Lund, A.M., Thomsen, C. (2013). Cerebral Magnetic Resonance Spectroscopy Demonstrates Long-Term Effect of Bone Marrow Transplantation in α-Mannosidosis. In: Zschocke, J., Gibson, K., Brown, G., Morava, E., Peters, V. (eds) JIMD Reports - Volume 11. JIMD Reports, vol 11. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2013_221
Download citation
DOI: https://doi.org/10.1007/8904_2013_221
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-37327-5
Online ISBN: 978-3-642-37328-2
eBook Packages: MedicineMedicine (R0)